EHA 2023 | Moving towards chemotherapy-free approaches in R/R follicular lymphoma
In this video, Marco Ladetto, MD, Hospital SS. Antonio e Biagio and Cesare Arrigo, Alessandria, Italy, provides insights into current and emerging treatment options for patients with relapsed/refractory follicular lymphoma (R/R FL). Dr Ladetto discussed the growing interest in chemotherapy-free regimens and combinatorial therapies, such as lenalidomide plus rituximab (R2), obinutuzumab plus zanubrutinib, and immune therapies like CAR-T therapy and monoclonal antibodies. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy, participation to advisory boards, invitation to scientific meetings, institutional research support and contracts with: AbbVie, Acerta, Amgen, ADC Therapeutics, BeiGene, Celgene/BMS, Eusapharma, GSKI, Gentili, Gilead/Kite, Lilly, Novartis, Incyte J&J, Jazz, Regeneron, Roche, Sandoz.
Non-financial interests:
PI or strategic investigator in studies supported by: Celgene, J&J, BeiGene, ADC Therapeutics
